Nicardipine Aguettant (Nicardipine Hydrochloride)

Nicardipine Hydrochloride, the active ingredient in Nicardipine Aguettant, is a calcium channel blocker (dihydropyridine) presented as an intravenous solution for intravenous use. It treats hypertension, angina pectoris and acute coronary syndrome in adult patients, and the formulation is intended for controlled infusion in acute‑care settings.

GNH USA supplies Nicardipine Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nicardipine is a dihydropyridine calcium channel blocker used in cardiovascular conditions that involve arterial constriction.

Hypertension: lowers systemic blood pressure by causing arterial vasodilation. Angina pectoris: relieves chest pain by improving myocardial oxygen delivery. Acute coronary syndrome: stabilises coronary circulation and reduces ischemic risk.

Adverse reactions may occur with nicardipine administration.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of skin. - Tachycardia: increased heart rate during infusion. - Peripheral edema: swelling of lower extremities.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring intervention. - Myocardial infarction: rare occurrence during rapid infusion. - Arrhythmias: potentially life‑threatening rhythm disturbances. - Allergic reactions: rash, bronchospasm, or anaphylaxis.

Careful monitoring and patient assessment are essential when using nicardipine.

Monitor blood pressure: check regularly during infusion. Assess cardiac function: avoid rapid infusion in severe aortic stenosis. Use caution in hepatic impairment: dose adjustment may be required. Avoid concomitant potent vasodilators: risk of additive hypotension. Store at ambient temperature: keep in original container, protect from light and moisture.

Nicardipine may interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Other calcium channel blockers (e.g., amlodipine): risk of excessive hypotension. - Nitrates: additive vasodilation may cause severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase nicardipine plasma levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask tachycardia. - Diuretics: can enhance hypotensive effect. - ACE inhibitors: monitor renal function and potassium balance.